Eloxx Pharmaceuticals, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Eloxx completed a $66.0M underwritten public offering (2,975,000 shares at $11/share plus 3,025,000 pre-funded warrants) in June 2026, netting $58.3M after underwriting costs. The company uplifted to Nasdaq Capital Market (ticker ELOX) and ended Q2 2026 with $62.0M cash, no debt, and stockholders' equity of $46.4M (vs. deficit of $11.9M at year-end 2025). Cash is projected to fund operations through mid-2028 clinical data readouts for exaluren in Alport syndrome (Phase 2b initiating Q3 2026, data mid-2027) and ADPKD (Phase 2 planned 2027, data mid-2028).
Why this rating
Funding extends runway 3+ years, transforms balance sheet from deficit to equity-positive, and eliminates near-term dilution risk—transformational for $330K market-cap biotech.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.